Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer

Fig. 5

Secondary analysis of PD-L1 immunohistochemical staining density. a Boxplot and scatter plot for PD-L1 density (Treated vs Control), mean PD-L1 density in the treated (0.0589) versus control samples (0.0833) was observed but was not significant: p = 0.245 for Welch two sample t-test comparing PD-L1+ cell density of tumor in treated group and historic control group, i.e. the mean PD-L1+ cell density in tumor was significantly lower in treated subjects compared to historical control subjects. b Within subject difference of PDL1 density: tumor minus adjacent normal tissue (Treated vs. Controls)

Back to article page